1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

New board appointment at Cellceutix

 
• By Zoë Dann

Dr Emil Frei is to serve on Cellceutix's scientific advisory board until June 30th, 2010. Dr Frei, a leading oncologist, has served in several leadership positions including chief of medicine at the National Cancer Institute, associate scientific director at MD Anderson and director and physician-in-chief at the Dana-Farber Cancer Institute. He continues to serve as physician-in-chief, emeritus, at Dana-Farber.

Dr Emil Frei is to serve on Cellceutix's scientific advisory board until June 30th, 2010. Dr Frei, a leading oncologist, has served in several leadership positions including chief of medicine at the National Cancer Institute, associate scientific director at MD Anderson and director and physician-in-chief at the Dana-Farber Cancer Institute. He continues to serve as physician-in-chief, emeritus, at Dana-Farber.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for their novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A, respectively.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Therapeutic Category

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.